News

On World Autism Awareness Day, we remain dedicated to supporting individuals on the spectrum, day and night. Together, let’s spread awareness, foster inclusion, and make a real difference. Watch this […]

We are pleased to share that Neurim Pharmaceuticals has received European Marketing Authorization for Pediatric Prolonged-Release Melatonin (Slenyto®) for the treatment of insomnia in children with Attention Deficit Hyperactivity Disorder […]

We are thrilled to announce the successful launch of Slenyto in South Korea on September 25th. This unique medication is set to make a significant impact, improving the lives of […]

We are excited to announce that Neurim Pharmaceuticals received a positive CHMP opinion on Slenyto® (Pediatric Prolonged-Release Melatonin) for the treatment of Insomnia in children with Neurogenetic Disorders (NGDs). This […]

Neurim Pharmaceuticals is attending IPSA 2024 Congress in Glasgow. We are delighted to invite IPSA 2024 attendees to participate in our satellite symposium “Advances in treatment of insomnia in children […]

We were thrilled to gather our international partners once more for a successful meeting focused on exchanging ideas and insights, all with the goal of promoting improved care for children […]

Neurim and partners are delighted to participate in ESCAP 2023 aiming to increase awareness for Insomnia in children with ASD.

We were delighted to have our international partners together, for another successful meeting, sharing ideas and insights, aiming at promoting better care of insomnia in children with ASD.

We are delighted to invite ESCAP 2022 attendees to participate in our satellite symposium “Screen, Evaluate and Treat Insomnia in Children with ASD” on Monday, June 20th at 12:30. Symposium […]